
Releases
ADMA Biologics Faces Securities Lawsuit Over Alleged Revenue Inflation
Investors who purchased ADMA Biologics stock between August 9, 2024, and March 25, 2026, face an August 10, 2026, deadline to seek lead plaintiff status in a pending securities class action. The lawsuit alleges the company misled shareholders by certifying internal controls while concealing channel stuffing and undisclosed related party transactions.
























